At a glance
ClinicalIndex Comparison RecordPhase 2Active· 64 enrolled
Drug / intervention
Lu AF82422 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of Lu AF82422 in Patients With Multiple System Atrophy
In Brief
A Phase 2 clinical trial evaluating Lu AF82422 and Placebo for Multiple System Atrophy. Active but no longer recruiting, targeting 64 participants across 19 sites in 2 countries.
Detailed Summary
To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple System Atrophy
CountriesJapan, United States
Collaborators--
Timeline
Phase 2Active
2022202320242025202620272028
First PostedNov 2021
Enrollment StartNov 2021
Primary CompletionNov 2023
TodayJul 2026
Study CompletionMar 2028
First PostedNov 3, 2021
Enrollment StartNov 16, 2021
Primary CompletionNov 16, 2023
Study CompletionMar 7, 2028
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 4.7 years ago
Interventions
Lu AF82422drug
Solution for infusion
Placebodrug
Solution for infusion